文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

宿主反应蛋白生物标志物提示重症COVID-19患者持续性急性肾损伤

Host Response Protein Biomarkers Indicative of Persistent Acute Kidney Injury in Critically Ill COVID-19 Patients.
PubMed 文献 · Crit Care Explor · 2025-03-13
一句话结论重症COVID-19患者中持续性AKI与炎症相关生物标志物升高相关,而非细胞因子信号、内皮激活或凝血域。

这项前瞻性生物标志物研究在2020年3月至7月三个ICU观察了177例无慢性肾脏病的重症SARS-CoV-2感染患者,通过每小时尿量和每日血浆肌酐评估AKI。106例(59.9%)在入ICU 48小时内发生AKI,其中76例(71.7%)为持续性AKI,30例(28.3%)为短暂性AKI。纵向分析显示,与无AKI相比,持续性AKI有7种蛋白升高,涉及炎症、补体激活、肾功能不全和肺功能障碍;AKI持续时间与细胞因子信号、内皮细胞激活或凝血域无关。作者认为与脓毒症相关AKI不同,COVID-AKI的持续性主要与炎症相关生物标志物水平相关。

要点

  • 177例重症COVID-19患者中106例(59.9%)在入ICU 48小时内发生AKI,其中76例(71.7%)为持续性AKI(>48小时),30例(28.3%)为短暂性AKI(<48小时)。
  • 持续性AKI患者常合并肥胖、高血压及因肾脏成分导致更高的SOFA评分。
  • 与无AKI相比,持续性AKI患者炎症标志物升高:触发髓样细胞表达受体1(p<0.001)、肿瘤坏死因子受体1(p<0.001)、降钙素原(p=0.001)。
  • 持续性AKI患者补体激活标志物甘露聚糖结合凝集素丝氨酸蛋白酶-2升高(p=0.001),肾功能不全标志物胱抑素C(p<0.001)和中性粒细胞明胶酶相关脂质运载蛋白(p<0.001)升高,肺功能障碍标志物Clara细胞分泌蛋白16升高(p<0.001)。
  • AKI持续时间与细胞因子信号、内皮细胞激活或凝血域的生物标志物差异无关。

适用人群与场景

  • 重症SARS-CoV-2感染成人患者,无慢性肾脏病,来自三个ICU,2020年3月至2020年7月。

诊断标准与关键阈值

  • AKI通过每小时尿量和每日血浆肌酐评估。
  • 持续性AKI定义为>48小时,短暂性AKI定义为<48小时,无AKI为对照。

研究设计与关键结果

  • 前瞻性生物标志物研究,纳入177例重症COVID-19患者,106例(59.9%)在入ICU 48小时内发生AKI,其中76例(71.7%)为持续性AKI,30例(28.3%)为短暂性AKI。
  • 持续性AKI患者常合并肥胖、高血压及因肾脏成分导致更高的SOFA评分。
  • 纵向分析显示,与无AKI相比,持续性AKI有7种蛋白升高:炎症域触发髓样细胞表达受体1(p<0.001)、肿瘤坏死因子受体1(p<0.001)、降钙素原(p=0.001);补体激活域甘露聚糖结合凝集素丝氨酸蛋白酶-2(p=0.001);肾功能不全域胱抑素C(p<0.001)、中性粒细胞明胶酶相关脂质运载蛋白(p<0.001);肺功能障碍域Clara细胞分泌蛋白16(p<0.001)。
  • AKI持续时间与细胞因子信号、内皮细胞激活或凝血域的生物标志物差异无关。

证据类型、等级与局限

  • 证据类型:前瞻性生物标志物研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与脓毒症相关AKI不同,COVID-AKI的持续性主要与炎症相关生物标志物水平相关,该研究为COVID-AKI提供了见解,可能指导减轻其持续性的方法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sepsis-related host-response anomalies contribute to acute kidney injury (AKI) duration. Data on the host-response specific to COVID-19-associated AKI (COVID-AKI) in critically ill patients is limited.

OBJECTIVES: We postulated that persistent COVID-AKI (> 48 hr) differs in host response from transient (< 48 hr) or no COVID-AKI.

DESIGN, SETTING, AND PARTICIPANTS: This prospective biomarker study observed patients with severe acute respiratory syndrome coronavirus 2 infection, without chronic kidney disease, in three ICUs from March 2020 to July 2020. AKI was assessed by hourly urine output and daily plasma creatinine.

MAIN OUTCOMES AND MEASURES: Luminex and enzyme-linked immunosorbent assay were used to analyze 48 plasma protein biomarkers across six pathophysiological domains, which were tested with mixed-effects models.

RESULTS: Of 177 included patients, 106 (59.9%) had AKI within the first 48 hours of admission, of whom 76 (71.7%) had persistent AKI and 30 (28.3%) transient AKI. Those with persistent AKI often had obesity, hypertension, and a higher Sequential Organ Failure Assessment score due to the renal component. Longitudinal analyses revealed that seven proteins were elevated in persistent AKI compared with no AKI. These were related to inflammation (triggering receptor expressed on myeloid cells 1, p < 0.001; tumor necrosis factor receptor 1, p < 0.001; procalcitonin, p = 0.001), complement activation (mannan-binding lectin serine protease-2, p = 0.001), kidney dysfunction (cystatin C, p < 0.001; neutrophil gelatinase-associated lipocalin, p < 0.001), and lung dysfunction (Clara cell secretory protein 16, p < 0.001). AKI (duration) was not associated with differences in the cytokine signaling, endothelial cell activation, or coagulation domains.

CONCLUSIONS AND RELEVANCE: In contrast with sepsis-associated AKI, primarily inflammation-related biomarker levels correlated with COVID-AKI persistence. This study offers insights into COVID-AKI and may guide approaches to mitigate its persistence.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Steenvoorden TS, de Kruijf KC, Appelman B, et al. Host Response Protein Biomarkers Indicative of Persistent Acute Kidney Injury in Critically Ill COVID-19 Patients. Crit Care Explor. 2025. PMID: 40079888. doi:10.1097/CCE.0000000000001222

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。